FDA FY ’27 Budget Proposes Broad New Authorities and Reforms Across Food, Drugs and Medical Devices

The Food and Drug Administration (FDA)’s FY 2027 budget proposal, which is the first fully developed under Commissioner Marty Makary’s tenure, includes a wide-ranging collection of legislative proposals that aim to expand the agency’s authorities across nearly every major product area it regulates, including drugs, biologics, food and medical devices. While most of the budget requests funding to carry out programs within FDA’s existing mandate, these proposals are requests for Congress to legislatively alter existing programs or create new authority in statute. In this alert, we provide a high-level overview of the new authorities FDA is seeking from Congress.

For more details, please click here.

THIS DOCUMENT IS INTENDED TO PROVIDE YOU WITH GENERAL INFORMATION REGARDING ADJUSTED THE WHITE HOUSES FY 2027 FDA BUDGET REQUEST. THE CONTENTS OF THIS DOCUMENT ARE NOT INTENDED TO PROVIDE SPECIFIC LEGAL ADVICE. IF YOU HAVE ANY QUESTIONS ABOUT THE CONTENTS OF THIS DOCUMENT OR IF YOU NEED LEGAL ADVICE AS TO AN ISSUE, PLEASE CONTACT THE ATTORNEYS LISTED OR YOUR REGULAR BROWNSTEIN HYATT FARBER SCHRECK, LLP ATTORNEY. THIS COMMUNICATION MAY BE CONSIDERED ADVERTISING IN SOME JURISDICTIONS.